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Abstract: Type 2 diabetes mellitus (T2DM) is a progressive disease associated with significant 
morbidity and mortality. There is good evidence that intensive glycemic control reduces the 
development and progression of complications in patients with diabetes. In order to achieve 
glycemic targets, patients often require a combination of oral therapy and/or insulin in addition to 
lifestyle modification. Unfortunately many currently available therapies for T2DM are associated 
with weight gain and hypoglycemia resulting in poor compliance and subsequent worsening 
glycemic control. Glucagon like peptide-1 (GLP-1) is an incretin hormone secreted from the small 
intestine that lowers fasting and postprandial glucose through multiple mechanisms including 
glucose-dependent insulin secretion, reduction of glucagon secretion, delaying gastric emptying 
and increased satiety. Liraglutide is a long acting GLP-1 mimetic that is administered once a 
day by subcutaneous injection and is now licensed for the treatment of T2DM. Phase 3 clinical 
trials have demonstrated beneficial effects on glycemic control and weight with liraglutide 
therapy. Within this article, we provide an overview of pharmacology, efficacy, safety and 
patient experience on liraglutide in the management of T2DM.
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Introduction
Type 2 diabetes mellitus (T2DM) is a progressive disease characterized by a 
  variable degree of β-cell dysfunction, insulin resistance and hyperglycemia. 
Chronic hyperglycemia plays a major role in the pathogenesis of micro and 
  macrovascular disease,1,2 and also potentates β-cell failure.3 Large controlled 
clinical trials have demonstrated that intensive glycemic control can significantly 
minimise the development and progression of complications in patients with 
  diabetes.4,5 In order to achieve glycemic control, patients with T2DM often require 
a combination of oral therapy and/or insulin in addition to lifestyle modifications. 
The United Kingdom Prospective Diabetes Study (UKPDS)6 reported that more 
than 50% of patients with T2DM will require multiple oral antidiabetic drugs 
(OAD) within three years after diagnosis. Furthermore, 9 years after diagnosis 
approximately 70% of patients required a combination of OAD with or without 
insulin therapy. This illustrates the complex progressive nature of T2DM which 
has proved difficult to treat to date.
Liraglutide
Liraglutide is the second in class of glucagon like peptide-1 (GLP-1) mimetics now 
available for the treatment of T2DM. The first product licensed was exenatide which Patient Preference and Adherence 2010:4 62
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is a twice-daily delivered functional partly dipeptidyl 
  peptidase-IV (DPP-IV) resistant analogue of human 
GLP-1 which is now in established use.7 GLP-1 mimetics 
improve glycemic control through multiple mechanisms 
similar to the  endogenous incretin hormone GLP-1.8,9 
GLP-1 is normally secreted by intestinal L-cells in 
response to food intake particularly carbohydrate, fat and 
proteins. It has multiple physiological actions including 
glucose-dependent insulin secretion and reduced glucagon 
  secretion. In addition, GLP-1 also reduces gastric emptying 
and increases satiety.10 In vivo, GLP-1 is rapidly inactivated 
by the enzyme DPP-IV resulting in a plasma half-life of 
1–2 minutes. To overcome this, DPP-IV resistant analogues 
of human GLP-1 have been developed for clinical use. 
  Liraglutide is an acylated derivative of GLP-1 currently 
available for the treatment of T2DM and may be regarded 
as the only true GLP-1 analogue. Prior to the introduction 
of incretin based therapies, apart from metformin, all other 
OAD induce weight gain and an increase in body mass 
index (BMI) especially in those with pre-existing obesity. 
In patients with T2DM such an increase in BMI worsens 
  insulin resistance and glycemic control. Furthermore, 
a raised BMI is an established cause for increased 
  cardiovascular mortality, particularly among individuals 
with diabetes.11 In addition to weight gain, the use of insulin 
sensitisers such as thiazolidinedione are reported to cause 
water retention and may exacerbate cardiac failure in some 
circumstances. Both insulin and insulin secretagogues are 
known to cause hypoglycemia with associated morbidity 
and a reduction in quality of life.12 These problems of 
treatment related weight gain, hypoglycemia and fear of 
hypoglycemia result in poor compliance and deteriorating 
glycemic control.13,14
Pharmacology of liraglutide
Liraglutide is a long-acting GLP-1 analogue with 97% 
sequence homology to human GLP-1. Chemically it is 
similar to human GLP-1, but with structural modifications 
including an amino acid substitution of an arginine at posi-
tion 34. There is also an addition of a C-16 acyl chain linked 
to a glutamate spacer at the lysine on position 26.15 These 
structural modifications result in reversible albumin binding, 
resistance to GLP-1 inactivation by DPP-IV and prolonged 
duration of action.16 Following subcutaneous injection, the 
absorption of liraglutide is slow with a maximal plasma 
  concentration 9 to 14 hours post delivery with an elimination 
half life of approximately 13 hours.17 Elimination studies 
have demonstrated that no intact liraglutide and only low 
levels of metabolites are detected in the urine or feces after 
administration.17 Liraglutide, like other large proteins is 
degraded in to small peptides, amino acids and fatty acids 
and eliminated through the liver and kidney. However, no 
single organ has been identified that plays a major part in 
  elimination and furthermore a proportion of the degraded 
fragments are recycled into new endogenous proteins and 
lipids.
Mode of action
The physiological actions of liraglutide are mediated 
via specific GLP-1 receptors. Liraglutide shares several 
  glucoregulatory actions with GLP-1 including enhancement 
of glucose-dependent insulin secretion, inhibition of 
  postprandial glucagon secretion, inhibition of gastric 
  emptying and reduction of food intake.18–21 In rodent studies, 
both GLP-1 and liraglutide promote the maintenance of β-cell 
mass in diabetes, presumably by inhibiting both cytokine 
and free fatty acid induced apoptosis.22 Furthermore, clinical 
studies with liraglutide have been observed to enhance 
β-cell function suggesting a potential role in preservation 
of β-cell.21
Safety and tolerability
Beneficial effects of liraglutide
Glycemic control
Treatment with liraglutide is associated with a significant 
improvement in glycated hemoglobin (HbA1c), fasting 
and postprandial glucose.23 Juhl et al, in a double-blind, 
  placebo-controlled, crossover study demonstrated a 
  substantial reduction of fasting and postprandial glycemia 
  following bedtime administration of liraglutide in patients 
with T2DM.24 Within this study the mean fasting plasma 
  glucose was significantly lower with liraglutide compared to 
placebo (6.9 ± 1.0 mmol/L vs 8.1 ± 1.0 mmol/L, P  0.01). 
Madsbad et al in a randomized, placebo-controlled trial over 
12 weeks reported a reduction in both fasting glucose and 
HbA1c with a once-daily dose of liraglutide.25 In this study 
the use of 0.75 mg liraglutide resulted in 0.75% reduction in 
HbA1c (P  0.0001) and 1.8 mmol/L (P = 0.0003) reduction 
in fasting glucose compared with placebo. The results of 
phase III clinical studies – Liraglutide Effects and Action in 
Diabetes (LEAD) – are available in publication. The LEAD 
program comprised 6 randomized controlled, double blind 
studies conducted in more than 40 countries which examined 
the effect of liraglutide directly against commonly used 
therapies in T2DM on HbA1c (Table 1). The LEAD-1 study26 
was a 26-week, double-dummy, multicenter, multinational Patient Preference and Adherence 2010:4 63
Liraglutide in type 2 diabetes mellitus Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
trial designed to compare the effect of combining liraglutide 
(0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day or 
  placebo with glimepiride (2–4 mg/day) in patients with 
T2DM. Liraglutide (1.2 mg or1.8 mg) added to glimepiride 
resulted in a greater reduction in both fasting as well as 
postprandial plasma glucose from baseline, compared to 
placebo or rosiglitazone. In addition, liraglutide was asso-
ciated with a greater reduction in HbA1c from the baseline 
compared with placebo or rosiglitazone (reduction in 
HbA1c from baseline –1.1% with liraglutide, +0.2% with 
placebo and –0.4% with rosiglitazone, P  0.0001). In the 
LEAD-2 study27 the efficacy and safety of liraglutide added 
to metformin was compared with addition of placebo or 
glimepiride to metformin. At the end of the 26-week trial 
period, it was observed that the treatment with liraglutide 
induced superior glycemic control compared with a placebo 
group and non inferior glycemic control compared to the 
glimepiride group.
The LEAD-3 study28 was a head to head comparison 
between liraglutide and glimepiride monotherapy. 
At 52 weeks, the percentage of patients reaching the 
American Diabetes Association target HbA1c of less 
than 7% were significantly higher in those treated with 
liraglutide compared to glimepiride monotherapy. Similar 
results were noted in LEAD-4 trial29 when liraglutide 
was added to metformin and rosiglitazone. Compared to 
placebo an approximate 0.9% reduction in HBA1c was 
observed with 1.2 mg or 1.8 mg of liraglutide compared 
to placebo (P  0.0001). Furthermore, LEAD-5 study 
30 demonstrated a significant improvement in glycemic 
control by adding liraglutide in patients already receiving 
metformin and a sulphonylurea compared with placebo and 
insulin glargine. The reduction in HBA1c was 1.3% in those 
receiving 1.8 mg of liraglutide compared to 1.09% in those 
receiving glargine insulin (P = 0.0015). In LEAD-6 study31 
the efficacy of liraglutide was compared with the exenatide 
as add-on therapy to metformin and/or sulphonylurea. 
Within this study, a greater improvement in glycemic 
control was noted with once daily liraglutide compared to 
twice a day exenatide (reduction in mean HbA1c of 1.12% 
with liraglutide and 0.7% with exenatide).
Body weight
Treatment with liraglutide results in sustained weight loss com-
pared to placebo. This was observed in all of the LEAD studies, 
except LEAD-126–31 (Table 1). Of interest, the maximum weight 
loss of –3.24 kg was observed in LEAD-6 which compared the 
efficacy of liraglutide and exenatide. The observed weight loss 
with liraglutide appears to be largely independent of nausea. 
Furthermore, a recent randomized, double-blind, placebo-
controlled study conducted in obese individuals without T2DM 
demonstrated a significant weight reduction associated with 
liraglutide at 20 weeks.32 In this study the mean weight loss 
observed with liraglutide doses of 1.2 mg, 1.8 mg, 2.4 mg, and 
3.0 mg were 4.8 kg, 5.5 kg, 6.3 kg, and 7.2 kg respectively, 
compared with 2.8 kg with placebo. Although many studies 
have demonstrated a significant weight loss with liraglutide, 
like exenatide it is not currently it is not licensed for use as a 
weight reducing agent.
β-cell function
Liraglutide has been shown to enhance β-cell mass in animal 
models.21 In addition to animal studies, clinical studies indi-
cate improved β-cell function as measured by the homeostasis 
model assessment for β-cell function (HOMA-B), secretion 
of C-peptide and proinsulin to insulin ratio. In phase 3 trials, 
treatment with liraglutide demonstrated significant decrease in 
the proinsulin to insulin ratio and improvement in  HOMA-B 
from the baseline compared to placebo.26,27,29
Cardiovascular system
A reduction in systolic blood pressure has also been observed 
with liraglutide as shown in Table 1.27–30 The mechanism for 
this is not well understood but appears to be independent of 
a reduction in body weight. Like native GLP-1, liraglutide 
inhibits tumor necrosis factor alpha (TNF) mediated 
  plasminogen activator inhibitor type-1 (PAI-1) activation 
in human vascular endothelial cells.33 These observations 
  suggest that a beneficial effect of liraglutide on endothelial 
dysfunction associated with premature atherosclerosis 
observed in T2DM. Evidence from randomized control 
  studies are yet to establish whether such improvement 
in biomarkers have an impact on long term micro and 
  macrovascular disease.
Adverse effects associated  
with liraglutide
Gastrointestinal
Like the other GLP-1 receptor agonist exenatide, a major 
adverse effect of liraglutide therapy is gastrointestinal 
disturbance with nausea, vomiting, and diarrhea being the 
commonest reported during clinical trials (Table 2). In 
early preclinical studies with low doses (0.7 5 mg), nau-
sea was reported by 10/135 patients exposed to liraglutide 
compared to 1/29 patients treated with placebo.25 Caution 
is required with this interpretation at such low doses but Patient Preference and Adherence 2010:4 64
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  nevertheless, in this study, approximately two-thirds of 
reported gastrointestinal events resolved within 1 to 3 days 
of continuing therapy and no patients withdrew from the 
  treatment due to gastrointestinal events. More clinically 
relevant doses prescribed in the phase 3 clinical trials have 
reported the incidence of nausea with liraglutide to range 
from 10% to 40% compared to 2% to 9% with the placebo 
group.26–29 In these trials nausea occurred early during 
  treatment and with continued therapy the frequency and 
severity decreased in majority of patients after the initial 
4 weeks of therapy. Similarly, diarrhea, vomiting, dyspepsia 
and constipation were often mild and noted to diminish within 
few days or weeks on continued therapy. The percentage of 
patients withdrawn because of gastrointestinal side effects 
like nausea, vomiting and diarrhea was low, ranging from   
2% to 5%.26–28 However, in LEAD-4 trial,29 the rate of 
  withdrawal was high at 11% with the higher dose of liraglu-
tide (1.8 mg/day). Since the gastrointestinal adverse effects 
are transient and dose depended liraglutide should be titrated 
from 0.6 mg at weekly increments.
Pancreatitis
Three cases of pancreatitis (1 patient in LEAD-1 and 2 patients 
in LEAD-3) have been reported during clinical trials with 
liraglutide. Compared to general population, patients with 
T2DM have a three fold risk of acute pancreatitis.34 Therefore, 
it is difficult to establish whether these reported cases are due to 
liraglutide therapy or to pre-existing increased risk. In view of 
confounding factors a causal relationship between liraglutide 
and pancreatitis may be difficult to establish however, a weak 
association cannot be excluded based on available clinical 
data.27,28 A similar view has been expressed for exenatide.35
Hypoglycemia
Minor hypoglycemic episodes were observed with liraglutide 
therapy during phase 3 clinical trials (Table 2). The frequency 
Table 1 Changes in HbA1c, weight and systolic blood pressure in the LEAD studies
Study Number Change in HbA1c (%) Change in body weight (kg) Change in systolic BP (%)
LEAD-126: Liraglutide added on to glimepiride (26 weeks duration)
Liraglutide 1.2 mg 228 −1.08 +0.32 −2.56
Liraglutide 1.8 mg 228 −1.13 −0.23 −2.81
Rosiglitazone 4 mg 228 −0.44 +2.11 −0.93
Placebo 114 +0.23 −0.10 −2.32
LEAD-227: Liraglutide added on to metformin (26 weeks duration)
Liraglutide 1.2 mg 228 −0.97 −2.58 −2.81
Liraglutide 1.8 mg 228 −1.00 −2.79 −2.29
Glimepiride 4 mg 228 −0.98 +0.95 +0.41
Placebo 114 +0.09 −1.51 −1.76
LEAD-328: Liraglutide as monotherapy (52 weeks duration)
Liraglutide 1.2 mg 234 −0.84 −2.05 −2.12
Liraglutide 1.8 mg 234 −1.14 −2.45 −3.64
Glimepiride 8 mg 234 −0.51 +1.12 −0.69
LEAD-429: Liraglutide added on to metformin + rosiglitazone (26 weeks duration)
Liraglutide 1.2 mg 178 −1.48 −1.02 −6.71
Liraglutide 1.8 mg 178 −1.48 −2.02 −5.65
Placebo 177 −0.54 +0.60 −1.11
LEAD-530: Liraglutide added on to metformin + glimepiride (26 weeks duration)
Liraglutide 1.8 mg 207 −1.33 −1.81 −3.97
Glargine 219 −1.09 +1.62 +0.54
Placebo   96 −0.24 −0.42 −1.44
LEAD-631: Liraglutide added on to metformin and/or sulfonylurea (26 weeks duration)
Liraglutide 1.8 mg 233 −1.12 −3.24 −2.51
Exenatide 10 µg 231 −0.79 −2.87 −2.00
Abbreviations: HbA1c, hemoglobin A1c; BP, blood pressure.Patient Preference and Adherence 2010:4 65
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of hypoglycemia varied depending on the oral hypoglycemic 
agents co-administered. This is in line with studies relating 
to exenatide.36 In a recent randomized controlled trial, it 
was reported that the incidence of minor hypoglycemia with 
liraglutide was comparable (3%) to placebo and 17% lower 
than with sulphonylurea.27 Another phase 3 trial reported 
minor hypoglycemia at a rate less than 0.5 episodes/patient 
year for liraglutide compared to 1.96 episodes/patient year 
with glimepiride.28 In a comparative study of liraglutide 
against insulin glargine when added to metformin and 
glimepiride, the incidence of minor hypoglycemia was 
similar (27% with liraglutide and 29% with glargine).30 
Within this study, 2.2% patients in the liraglutide treated 
arm had major hypoglycemia (none of these was noc-
turnal hypoglycemia) compared to none in the glargine 
group. Similarly, studies with exenatide have described an 
increased risk of hypoglycemia when co-administered with 
a sulphonylurea.37,38 Of interest, a study in mice examining 
GLP-1 in relation to tolbutamide, observed that uncoupling 
of GLP-1 from its glucose dependence was observed with 
tolbutamide.39 It is possible that such a mechanism may play 
a role in the increased hypoglycemia observed in diabetic 
patients receiving combination therapy of sulphonylurea and 
a GLP-1 agonist. Therefore, both patients and health carers 
should exercise increased vigilance for this potential adverse 
effect particularly when using combination of liraglutide 
with sulphonylurea.
Immunogenicity
Treatment with liraglutide may elicit an immune response 
leading to anti-liraglutide antibody production. During phase 
3 clinical trials anti-liraglutide antibodies have been detected 
in 4% to 13% of liraglutide recipients;26,28,29 however, these 
antibodies did not appears to alter the efficacy of lira-
glutide among the trial subjects. Moreover, compared to 
  exenatide (41%–49%) the incidence of antibody formation is 
Table 2 Nausea and hypoglycemia as common adverse effects in the LEAD studies
Study Nausea (%) aHypoglycemia major (%) bHypoglycemia minor (%)
LEAD-126
Liraglutide 1.2 mg 10.5 0   9.2
Liraglutide 1.8 mg 6.8 0.4   8.1
Rosiglitazone 4 mg 1.7 0   4.3
Placebo 2.5 0   2.6
LEAD-227
Liraglutide 1.2 mg 16.2 0   3.3
Liraglutide 1.8 mg 17.7 0   6.6
Glimepiride 4 mg 3.3 0 26.9
Placebo 3.3 0   5.8
LEAD-328
Liraglutide 1.2 mg 27.5 0 11.2
Liraglutide 1.8 mg 29.3 0 17.7
Glimepiride 8 mg 8.5 0 24.2
LEAD-429
Liraglutide 1.2 mg 30.5 0   9.0
Liraglutide 1.8 mg 40.4 0   7.9
Placebo 8.6 0   5.1
LEAD-530
Liraglutide 1.8 mg 13.9 2.2 27.4
Glargine 1.3 0 28.9
Placebo 3.5 0 16.7
LEAD-631
Liraglutide 1.8 mg 26.0 0 26.0
Exenatide 10 µg 28.0 0.9 34.0
aHypoglycemic episodes requiring third-party assistance.
bSelf treated hypoglycemic episodes.Patient Preference and Adherence 2010:4 66
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  significantly lower with liraglutide treatment which is thought 
to be due to the high degree of homology of liraglutide to 
human GLP-1.36
Lipohypertrophy
Lipohypertrophy is a common problem associated with 
long-term insulin therapy.40,41 There are no studies 
  available yet to confirm such skin changes are possible 
with liraglutide therapy. In a previous clinical trial, 
the subcutaneous use of liraglutide is noted to cause 
injection site bruising however, the frequency was no 
different compared to placebo injection (5.7% vs 5.9% 
of participants).42 In another study,25 mild injection site 
urticarial reaction was noted in 1 of the 135 participants 
treated with liraglutide.
Children, pregnancy and lactation
The use of liraglutide has not been studied in pediatrics and 
its use is not recommended for those aged below 18 years. 
There are no controlled trials examining the effects of 
  liraglutide on fertility or its teratogenic potential in pregnant 
women. Fertility studies in animals did not show a direct 
harmful effect on fertility; however, maternal administration 
of liraglutide at mid-gestation caused minor and reversible 
skeletal changes in fetal rats and rabbits. The safety of 
  liraglutide during lactation has not been established. Current 
recommendation by manufacturers is not to use liraglutide 
during pregnancy and breast feeding.
Patient reported outcomes
Much of the available information on patient outcomes 
reported to date are in abstract form. Within LEAD-2, the 
Diabetes Treatment Satisfaction Questionnaire (DTSQ) and 
Impact of Weight on Quality Of Life (IWQOL-Lite) were 
examined in relation to liraglutide as add-on therapy to 
metformin compared to placebo or glimepiride.43 Liraglutide 
was associated with a significant reduction in perceived 
hypoglycemia and hyperglycemia. Furthermore, there was a 
significant reduction in the public stress domain (ie, distress 
about weight when out in public) in those who received 
liraglutide. Within the LEAD-6 study, patient reported 
outcomes were recorded in 379 patients using the Diabetes 
Treatment Satisfaction Questionnaire score (DTSQs).44 It 
was observed that the highest treatment satisfaction was 
with liraglutide compared to exenatide (P  0.0001). Of 
interest within the questionnaire, liraglutide was superior to 
exenatide in respect to ‘current treatment’, ‘convenience’, 
‘flexibility’, ‘recommend’ and ‘continue’. The proportion 
of ‘satisfied’ patients (DTSQ-change 6) was 94% with 
liraglutide compared to 86% with exenatide (P = 0.0176). 
Patients also perceived significantly less hypoglycemia 
and hyperglycemia. Of note, in the extension phase of the 
trial the DTSQs remained stable in those who continued on 
  liraglutide and improved significantly in those who switched 
from exenatide to liraglutide.
Conclusion
It is evident from the phase 3 clinical trials that treatment 
with liraglutide is associated with significant improvement 
in fasting and postprandial glucose and HbA1c. In addition, 
liraglutide is shown to induce satiety and promote weight 
loss. Hence for patients not controlled by ‘traditional’ 
OADs, liraglutide is well designed to target many of the 
phenotypic features associated with T2DM. The relative 
weight loss compared to typical weight gain with insulin, 
sulphonylurea and thiazolidinedione therapy is clearly a 
benefit in T2DM. Liraglutide is well tolerated and the most 
common adverse effect like gastrointestinal disturbances are 
transient and dose dependent. Therefore, it is recommended 
that liraglutide should be titrated from 0.6 mg at weekly 
increments. It would appear from the available literature to 
date (summarized in Table 1) that the overall reduction in 
HBA1c is similar between the 1.2 mg and 1.8 mg dose, but 
there is clearly a price increment between these doses. Of 
interest the withdrawal rate from trials was also higher with 
the higher dose. This may explain why certain health boards 
and primary care trusts currently recommend use at a dose 
up to the 1.2 mg. Although the incidence of hypoglycemia 
is low with liraglutide, caution is required with co-existing 
sulphonylurea use as hypoglycemia may be more frequent. 
Compared to the recommended twice daily injections of 
exenatide, liraglutide with its once daily use may provide an 
additional advantage within this class of agents and might 
enhance patient acceptability and compliance.
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